Abstract
Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%≈50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for clinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as “advanced clinical medicine” by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as “social insurance” for further wide clinical application.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schipper DL, Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7:137–149
Macdonald JS, Gohmann JJ (1988) Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15:(Suppl 4) 42–49
Kondo T, Kubota T, Tanimura T, Yamaue H, Akiyama S, Maehara Y, Tanigawa T, Kitajima M, Takagi H, Japan Research Society for Appropriate Cancer Chemotherapy (2000) Cumulative results of chemosensitivity tests for antitumor agents in Japan. Anticancer Res 20:2389–2392
Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447
Nakajima T (1995) Review of adjuvant chemotherapy for gastric cancer. World J Surg 19:570–574
Saikawa Y, Kubota T, Furukawa T, Suto A, Watanabe M, Kumai K, Ishibiki K, Kitajima M (1994) Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 85:762–765
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Shimoyama Y, Kubota T, Watanabe M, Ishibiki K, Abe O (1989) Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to clonogenic assay. J Surg Oncol 41:12–18
Suto A, Kubota T, Shimoyama Y, Ishibiki K, Abe O (1989) MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42:28–32
Furukawa T, Kubota T, Suto A, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M (1991) Clinical usefulness of chemosensitivity testing using the MTTassay. J Surg Oncol 48:188–193
Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M, Hoffman RM (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498
Furukawa T, Kubota T, Watanabe M, Kase S, Takahara T, Yamaguchi H, Takeuchi T, Teramoto T, Ishibiki K, Kitajima M, Hoffman RM (1992) Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and MTT endpoint. Anticancer Res 12:1377–1382
Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311
Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, Nagura H, Ogawa N, Hoffman RM, Chemosensitivity Group for HDRA (1995) Potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537–1543
Macdonald JS, Gohmann JJ (1988) Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15 (Suppl. 4):42–49
Langenbach RJ, Danenberg PV and Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2’-deoxyuridylate. Biochem Biophys Res Commun 48:1565–1571
Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12:2035–2042
Johnston PG, Fisher ER, Rockette H. Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640–2647
Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM (1986) Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5’-deoxy-5-fluorouridine in relation to drugmetabolizing enzymes. Cancer Res 46:20–28
Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedule. Cancer Res 52:1855–1864
Spears CP, Shahinian AH, Moran RG, Heidelberger, Corbett TH (1982) In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and-resistant murine colon adenocarcinomas. Cancer Res 42:450–456
Naguib FNM, el Kouni MH, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45:5405–5412
Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai, K, Kitajima M, Takechi T, Okabe H, Fukushima M (1999) Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5:883–889
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kubota, T., Otani, Y., Furukawa, T., Hasegawa, H., Watanabe, M., Kitajima, M. (2003). Chemosensitivity Testing - Present and Future in Japan. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive